Blanck (et al. 2007). Use of nonprescription dietary supplements for weight loss is common among Americans. Journal of the American Dietetic Organization. 107(3):441-7.
Dietary supplements. (2012). FDA. Retrieved:
FDA regulation of nutritional supplements. (2012). FDA. Retrieved:
Overweight and obesity statistics. (2012). Weight Control Information Network (WIN).
Public notification: "Japan Rapid Weight Loss Diet Pills Yellow" contains hidden drug
Ingredient. (2012). FDA. Retrieved: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/MedicationHealthFraud/ucm298539.htm
Q&A about tainted weight loss products. (2011). FDA. Retrieved:
Over-the-counter and herbal remedies for weight loss. (2011). WebMD. Retrieved:
Tainted weight loss products. (2012). FDA. Retrieved:
FDA.gov. (2009). 510(K) Substantial Equivalence decision making process. FDA.gov. Retrieved April 16, 2012 from http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134783.htm?utm_source=fdaSearch&utm_medium=website&utm_term=substantial%20equivalence&utm_content=10
FDA.gov. (2009) How to prepare a traditional 510(K). FDA.gov. Retrieved April 16, 2012 from http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134572.htm
FDA.gov. (2010). Medical devices. FDA.gov. Retrieved April 16, 2012 fromhttp://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/default.htm
AAD (2005). Botulinum toxin. American Academy of Dermatology. Retrieved on July
25, 2010 from http://www.aad.org/public/publications/pamphlets/cosmetic_botulinum.html
Benesh, P. (2010). Allergan's botox nears U.S. approval to treat migraine. Investors Business Daily: Investors Business Daily, Inc. Retrieved on July 25, 2010 from http://www.investors.com/NewsAndAnalysis/Article/541624/201007261859/Allergan-Botox-Nears-U.S.-Approval-To-Treat-Migraine.aspx
Duthie J. et al. (2008). Botulinium toxin injection for adults with overactive bladder syndrome. Issue 3, The Cochrane Collaboration: Wiley Publishers.
Ellsworth P. And Kirshenbaum E. (2010). Update on the pharmacologic management of overactive bladder: the present and the future. 30 (1) Urologic Nursing; Society of Urologic Nurses and Associates
FDA (2002). The drug development and approval process. FDA Review: Independent
Institute. Retrieved on July 24, 2010 from http://www.fdareview.org/approval_process.shtml
Havinghurst, C.C. (2000). American healthcare and the law. 19 (4) Health Affairs:
Project HOPE. Retrieved on July 24, 2010 from http://www.medscape.com/viewarticle/409824
Herskovits, B. (2004). The botox craze: are injections appropriate for every practice?
Ocular Surgery News: OSN Supersite. Retrieved on July 25, 2010 from http://www.osunsupersie.com
Hori, S. et al. (2009). Patients' perspective of botulinum toxin A as a long-term treatment option for neurogenic detrusor over-activity secondary to spinal cord injury. Journal compilation doi:10.1111/j.1464-410X.2009.08368.x. BJU International: Blackwell
Karsenty, G. et al. (2007). Botulinum toxin a (Botox) intradetrusor injections in adults
with neurogenic detrusor over-activity/neurogenic overactive bladder. European Association of Urology: Elsevier B.V.
Moore, C. et al. (2005). Urologic application of botox. Glickman Urological Institute:
Cleveland Clinic Foundation
Sahai, A., et al. (2009). Improvement in quality of life after botulinum toxin -- A injection for idiopathic detrusor over-activity. 103 Journal Compilation. BJU International:
Medical Device Reporting - General Information www.rcb.ca.gov/forms_pubs/attach6.pdf
FDA - Medical Device Reporting (MDR) http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm